In Vivo CRO Market (2025 - 2030) Size, Share & Trends Analysis Report By Model Type (Rodent Based, Non-Rodent Based), By Modality (Small Molecule, Large Molecule), By Indication, By GLP Type, By Region, And Segment Forecasts

Market Segmentation

• Modality Outlook (Revenue, USD Million, 2018 - 2030)
  • Small Molecules
  • Large Molecules
    • Cell & Gene Therapy
      • CAR T-cell therapies
      • CAR-NK cell therapy
      • TCR-T cell therapy
      • Other
    • RNA Therapy
    • Others
• Model Type Outlook (Revenue, USD Million, 2018 - 2030)
  • Rodent based
    • Rat Models
    • Mice Models
    • Others
  • Non-Rodent based
• Indication Outlook (Revenue, USD Million, 2018 - 2030) 
  • Autoimmune/inflammation conditions
    • Rheumatoid Arthritis
    • Multiple Sclerosis
    • Osteoarthritis
    • Irritable Bowel Syndrome
    • Others
  • Pain management
    • Chronic pain
    • Acute pain
  • Oncology
    • Blood cancer
    • Solid tumor
      • Syngeneic model
      • Patient derived xenograft
      • Xenograft
    • Others
  • CNS Conditions
    • Epilepsy
    • Parkinson's disease
    • Huntington's disease
    • Stroke
    • Muscular Dystrophy
    • Alzheimer’s Disease
    • Traumatic brain injury
    • Amyotrophic lateral sclerosis (ALS)
    • Spinal Muscular Atrophy
    • Muscle regeneration
    • Other Neurodevelopment Disorders
  • Diabetes
  • Obesity
  • Others
• GLP Type Outlook (Revenue, USD Million, 2018 - 2030)
  • GLP Toxicology
  • Non GLP
• Regional Outlook (Revenue, USD Million, 2018 - 2030)
  • North America
    • North America Modality Outlook (Revenue in USD Million, 2018 - 2030)
      • Small Molecules
      • Large Molecules
        • Cell & Gene Therapy
          • CAR T-cell therapies
          • CAR-NK cell therapy
          • TCR-T cell therapy
          • Other
        • RNA Therapy
        • Others
    • North America Model Type Outlook (Revenue in USD Million, 2018 - 2030)
      • Rodent based
        • Rat Models
        • Mice Models
        • Others
      • Non-Rodent based
    • North America Indication Outlook (Revenue in USD Million, 2018 - 2030)
      • Autoimmune/inflammation conditions
        • Rheumatoid Arthritis
        • Multiple Sclerosis
        • Osteoarthritis
        • Irritable Bowel Syndrome
        • Others
      • Pain management
        • Chronic pain
        • Acute pain
      • Oncology
        • Blood cancer
        • Solid tumor
          • Syngeneic model
          • Patient derived xenograft
          • Xenograft
        • Others
      • CNS Conditions
        • Epilepsy
        • Parkinson's disease
        • Huntington's disease
        • Stroke
        • Muscular Dystrophy
        • Alzheimer’s Disease
        • Traumatic brain injury
        • Amyotrophic lateral sclerosis (ALS)
        • Spinal Muscular Atrophy
        • Muscle regeneration
        • Other Neurodevelopment Disorders
      • Diabetes
      • Obesity
      • Others
    • North America GLP Type Outlook (Revenue in USD Million, 2018 - 2030)
      • GLP Toxicology
      • Non GLP
    • U.S.
      • U.S. Modality Outlook (Revenue in USD Million, 2018 - 2030)
        • Small Molecules
        • Large Molecules
          • Cell & Gene Therapy
            • CAR T-cell therapies
            • CAR-NK cell therapy
            • TCR-T cell therapy
            • Other
          • RNA Therapy
          • Others
      • U.S. Model Type Outlook (Revenue in USD Million, 2018 - 2030)
        • Rodent based
          • Rat Models
          • Mice Models
          • Others
        • Non-Rodent based
      • U.S. Indication Outlook (Revenue in USD Million, 2018 - 2030)
        • Autoimmune/inflammation conditions
          • Rheumatoid Arthritis
          • Multiple Sclerosis
          • Osteoarthritis
          • Irritable Bowel Syndrome
          • Others
        • Pain management
          • Chronic pain
          • Acute pain
        • Oncology
          • Blood cancer
          • Solid tumor
            • Syngeneic model
            • Patient derived xenograft
            • Xenograft
          • Others
        • CNS Conditions
          • Epilepsy
          • Parkinson's disease
          • Huntington's disease
          • Stroke
          • Muscular Dystrophy
          • Alzheimer’s Disease
          • Traumatic brain injury
          • Amyotrophic lateral sclerosis (ALS)
          • Spinal Muscular Atrophy
          • Muscle regeneration
          • Other Neurodevelopment Disorders
        • Diabetes
        • Obesity
        • Others
      • U.S. GLP Type Outlook (Revenue in USD Million, 2018 - 2030)
        • GLP Toxicology
        • Non GLP
    • Canada
      • Canada Modality Outlook (Revenue in USD Million, 2018 - 2030)
        • Small Molecules
        • Large Molecules
          • Cell & Gene Therapy
            • CAR T-cell therapies
            • CAR-NK cell therapy
            • TCR-T cell therapy
            • Other
          • RNA Therapy
          • Others
      • Canada Model Type Outlook (Revenue in USD Million, 2018 - 2030)
        • Rodent based
          • Rat Models
          • Mice Models
          • Others
        • Non-Rodent based
      • Canada Indication Outlook (Revenue in USD Million, 2018 - 2030)
        • Autoimmune/inflammation conditions
          • Rheumatoid Arthritis
          • Multiple Sclerosis
          • Osteoarthritis
          • Irritable Bowel Syndrome
          • Others
        • Pain management
          • Chronic pain
          • Acute pain
        • Oncology
          • Blood cancer
          • Solid tumor
            • Syngeneic model
            • Patient derived xenograft
            • Xenograft
          • Others
        • CNS Conditions
          • Epilepsy
          • Parkinson's disease
          • Huntington's disease
          • Stroke
          • Muscular Dystrophy
          • Alzheimer’s Disease
          • Traumatic brain injury
          • Amyotrophic lateral sclerosis (ALS)
          • Spinal Muscular Atrophy
          • Muscle regeneration
          • Other Neurodevelopment Disorders
        • Diabetes
        • Obesity
        • Others
      • Canada GLP Type Outlook (Revenue in USD Million, 2018 - 2030)
        • GLP Toxicology
        • Non GLP
    • Mexico
      • Mexico Modality Outlook (Revenue in USD Million, 2018 - 2030)
        • Small Molecules
        • Large Molecules
          • Cell & Gene Therapy
            • CAR T-cell therapies
            • CAR-NK cell therapy
            • TCR-T cell therapy
            • Other
          • RNA Therapy
          • Others
      • Mexico Model Type Outlook (Revenue in USD Million, 2018 - 2030)
        • Rodent based
          • Rat Models
          • Mice Models
          • Others
        • Non-Rodent based
      • Mexico Indication Outlook (Revenue in USD Million, 2018 - 2030)
        • Autoimmune/inflammation conditions
          • Rheumatoid Arthritis
          • Multiple Sclerosis
          • Osteoarthritis
          • Irritable Bowel Syndrome
          • Others
        • Pain management
          • Chronic pain
          • Acute pain
        • Oncology
          • Blood cancer
          • Solid tumor
            • Syngeneic model
            • Patient derived xenograft
            • Xenograft
          • Others
        • CNS Conditions
          • Epilepsy
          • Parkinson's disease
          • Huntington's disease
          • Stroke
          • Muscular Dystrophy
          • Alzheimer’s Disease
          • Traumatic brain injury
          • Amyotrophic lateral sclerosis (ALS)
          • Spinal Muscular Atrophy
          • Muscle regeneration
          • Other Neurodevelopment Disorders
        • Diabetes
        • Obesity
        • Others
      • Mexico GLP Type Outlook (Revenue in USD Million, 2018 - 2030)
        • GLP Toxicology
        • Non GLP
  • Europe
    • Europe Modality Outlook (Revenue in USD Million, 2018 - 2030)
      • Small Molecules
      • Large Molecules
        • Cell & Gene Therapy
          • CAR T-cell therapies
          • CAR-NK cell therapy
          • TCR-T cell therapy
          • Other
        • RNA Therapy
        • Others
    • Europe Model Type Outlook (Revenue in USD Million, 2018 - 2030)
      • Rodent based
        • Rat Models
        • Mice Models
        • Others
      • Non-Rodent based
    • Europe Indication Outlook (Revenue in USD Million, 2018 - 2030)
      • Autoimmune/inflammation conditions
        • Rheumatoid Arthritis
        • Multiple Sclerosis
        • Osteoarthritis
        • Irritable Bowel Syndrome
        • Others
      • Pain management
        • Chronic pain
        • Acute pain
      • Oncology
        • Blood cancer
        • Solid tumor
          • Syngeneic model
          • Patient derived xenograft
          • Xenograft
        • Others
      • CNS Conditions
        • Epilepsy
        • Parkinson's disease
        • Huntington's disease
        • Stroke
        • Muscular Dystrophy
        • Alzheimer’s Disease
        • Traumatic brain injury
        • Amyotrophic lateral sclerosis (ALS)
        • Spinal Muscular Atrophy
        • Muscle regeneration
        • Other Neurodevelopment Disorders
      • Diabetes
      • Obesity
      • Others
    • Europe GLP Type Outlook (Revenue in USD Million, 2018 - 2030)
      • GLP Toxicology
      • Non GLP
    • U.K.
      • U.K. Modality Outlook (Revenue in USD Million, 2018 - 2030)
        • Small Molecules
        • Large Molecules
          • Cell & Gene Therapy
            • CAR T-cell therapies
            • CAR-NK cell therapy
            • TCR-T cell therapy
            • Other
          • RNA Therapy
          • Others
      • U.K. Model Type Outlook (Revenue in USD Million, 2018 - 2030)
        • Rodent based
          • Rat Models
          • Mice Models
          • Others
        • Non-Rodent based
      • U.K. Indication Outlook (Revenue in USD Million, 2018 - 2030)
        • Autoimmune/inflammation conditions
          • Rheumatoid Arthritis
          • Multiple Sclerosis
          • Osteoarthritis
          • Irritable Bowel Syndrome
          • Others
        • Pain management
          • Chronic pain
          • Acute pain
        • Oncology
          • Blood cancer
          • Solid tumor
            • Syngeneic model
            • Patient derived xenograft
            • Xenograft
          • Others
        • CNS Conditions
          • Epilepsy
          • Parkinson's disease
          • Huntington's disease
          • Stroke
          • Muscular Dystrophy
          • Alzheimer’s Disease
          • Traumatic brain injury
          • Amyotrophic lateral sclerosis (ALS)
          • Spinal Muscular Atrophy
          • Muscle regeneration
          • Other Neurodevelopment Disorders
        • Diabetes
        • Obesity
        • Others
      • U.K. GLP Type Outlook (Revenue in USD Million, 2018 - 2030)
        • GLP Toxicology
        • Non GLP
    • Germany
      • Germany Modality Outlook (Revenue in USD Million, 2018 - 2030)
        • Small Molecules
        • Large Molecules
          • Cell & Gene Therapy
            • CAR T-cell therapies
            • CAR-NK cell therapy
            • TCR-T cell therapy
            • Other
          • RNA Therapy
          • Others
      • Germany Model Type Outlook (Revenue in USD Million, 2018 - 2030)
        • Rodent based
          • Rat Models
          • Mice Models
          • Others
        • Non-Rodent based
      • Germany Indication Outlook (Revenue in USD Million, 2018 - 2030)
        • Autoimmune/inflammation conditions
          • Rheumatoid Arthritis
          • Multiple Sclerosis
          • Osteoarthritis
          • Irritable Bowel Syndrome
          • Others
        • Pain management
          • Chronic pain
          • Acute pain
        • Oncology
          • Blood cancer
          • Solid tumor
            • Syngeneic model
            • Patient derived xenograft
            • Xenograft
          • Others
        • CNS Conditions
          • Epilepsy
          • Parkinson's disease
          • Huntington's disease
          • Stroke
          • Muscular Dystrophy
          • Alzheimer’s Disease
          • Traumatic brain injury
          • Amyotrophic lateral sclerosis (ALS)
          • Spinal Muscular Atrophy
          • Muscle regeneration
          • Other Neurodevelopment Disorders
        • Diabetes
        • Obesity
        • Others
      • Germany GLP Type Outlook (Revenue in USD Million, 2018 - 2030)
        • GLP Toxicology
        • Non GLP
    • France
      • France Modality Outlook (Revenue in USD Million, 2018 - 2030)
        • Small Molecules
        • Large Molecules
          • Cell & Gene Therapy
            • CAR T-cell therapies
            • CAR-NK cell therapy
            • TCR-T cell therapy
            • Other
          • RNA Therapy
          • Others
      • France Model Type Outlook (Revenue in USD Million, 2018 - 2030)
        • Rodent based
          • Rat Models
          • Mice Models
          • Others
        • Non-Rodent based
      • France Indication Outlook (Revenue in USD Million, 2018 - 2030)
        • Autoimmune/inflammation conditions
          • Rheumatoid Arthritis
          • Multiple Sclerosis
          • Osteoarthritis
          • Irritable Bowel Syndrome
          • Others
        • Pain management
          • Chronic pain
          • Acute pain
        • Oncology
          • Blood cancer
          • Solid tumor
            • Syngeneic model
            • Patient derived xenograft
            • Xenograft
          • Others
        • CNS Conditions
          • Epilepsy
          • Parkinson's disease
          • Huntington's disease
          • Stroke
          • Muscular Dystrophy
          • Alzheimer’s Disease
          • Traumatic brain injury
          • Amyotrophic lateral sclerosis (ALS)
          • Spinal Muscular Atrophy
          • Muscle regeneration
          • Other Neurodevelopment Disorders
        • Diabetes
        • Obesity
        • Others
      • France GLP Type Outlook (Revenue in USD Million, 2018 - 2030)
        • GLP Toxicology
        • Non GLP
    • Italy
      • Italy Modality Outlook (Revenue in USD Million, 2018 - 2030)
        • Small Molecules
        • Large Molecules
          • Cell & Gene Therapy
            • CAR T-cell therapies
            • CAR-NK cell therapy
            • TCR-T cell therapy
            • Other
          • RNA Therapy
          • Others
      • Italy Model Type Outlook (Revenue in USD Million, 2018 - 2030)
        • Rodent based
          • Rat Models
          • Mice Models
          • Others
        • Non-Rodent based
      • Italy Indication Outlook (Revenue in USD Million, 2018 - 2030)
        • Autoimmune/inflammation conditions
          • Rheumatoid Arthritis
          • Multiple Sclerosis
          • Osteoarthritis
          • Irritable Bowel Syndrome
          • Others
        • Pain management
          • Chronic pain
          • Acute pain
        • Oncology
          • Blood cancer
          • Solid tumor
            • Syngeneic model
            • Patient derived xenograft
            • Xenograft
          • Others
        • CNS Conditions
          • Epilepsy
          • Parkinson's disease
          • Huntington's disease
          • Stroke
          • Muscular Dystrophy
          • Alzheimer’s Disease
          • Traumatic brain injury
          • Amyotrophic lateral sclerosis (ALS)
          • Spinal Muscular Atrophy
          • Muscle regeneration
          • Other Neurodevelopment Disorders
        • Diabetes
        • Obesity
        • Others
      • Italy GLP Type Outlook (Revenue in USD Million, 2018 - 2030)
        • GLP Toxicology
        • Non GLP
    • Spain
      • Spain Modality Outlook (Revenue in USD Million, 2018 - 2030)
        • Small Molecules
        • Large Molecules
          • Cell & Gene Therapy
            • CAR T-cell therapies
            • CAR-NK cell therapy
            • TCR-T cell therapy
            • Other
          • RNA Therapy
          • Others
      • Spain Model Type Outlook (Revenue in USD Million, 2018 - 2030)
        • Rodent based
          • Rat Models
          • Mice Models
          • Others
        • Non-Rodent based
      • Spain Indication Outlook (Revenue in USD Million, 2018 - 2030)
        • Autoimmune/inflammation conditions
          • Rheumatoid Arthritis
          • Multiple Sclerosis
          • Osteoarthritis
          • Irritable Bowel Syndrome
          • Others
        • Pain management
          • Chronic pain
          • Acute pain
        • Oncology
          • Blood cancer
          • Solid tumor
            • Syngeneic model
            • Patient derived xenograft
            • Xenograft
          • Others
        • CNS Conditions
          • Epilepsy
          • Parkinson's disease
          • Huntington's disease
          • Stroke
          • Muscular Dystrophy
          • Alzheimer’s Disease
          • Traumatic brain injury
          • Amyotrophic lateral sclerosis (ALS)
          • Spinal Muscular Atrophy
          • Muscle regeneration
          • Other Neurodevelopment Disorders
        • Diabetes
        • Obesity
        • Others
      • Spain GLP Type Outlook (Revenue in USD Million, 2018 - 2030)
        • GLP Toxicology
        • Non GLP
    • Denmark
      • Denmark Modality Outlook (Revenue in USD Million, 2018 - 2030)
        • Small Molecules
        • Large Molecules
          • Cell & Gene Therapy
            • CAR T-cell therapies
            • CAR-NK cell therapy
            • TCR-T cell therapy
            • Other
          • RNA Therapy
          • Others
      • Denmark Model Type Outlook (Revenue in USD Million, 2018 - 2030)
        • Rodent based
          • Rat Models
          • Mice Models
          • Others
        • Non-Rodent based
      • Denmark Indication Outlook (Revenue in USD Million, 2018 - 2030)
        • Autoimmune/inflammation conditions
          • Rheumatoid Arthritis
          • Multiple Sclerosis
          • Osteoarthritis
          • Irritable Bowel Syndrome
          • Others
        • Pain management
          • Chronic pain
          • Acute pain
        • Oncology
          • Blood cancer
          • Solid tumor
            • Syngeneic model
            • Patient derived xenograft
            • Xenograft
          • Others
        • CNS Conditions
          • Epilepsy
          • Parkinson's disease
          • Huntington's disease
          • Stroke
          • Muscular Dystrophy
          • Alzheimer’s Disease
          • Traumatic brain injury
          • Amyotrophic lateral sclerosis (ALS)
          • Spinal Muscular Atrophy
          • Muscle regeneration
          • Other Neurodevelopment Disorders
        • Diabetes
        • Obesity
        • Others
      • Denmark GLP Type Outlook (Revenue in USD Million, 2018 - 2030)
        • GLP Toxicology
        • Non GLP
    • Sweden
      • Sweden Modality Outlook (Revenue in USD Million, 2018 - 2030)
        • Small Molecules
        • Large Molecules
          • Cell & Gene Therapy
            • CAR T-cell therapies
            • CAR-NK cell therapy
            • TCR-T cell therapy
            • Other
          • RNA Therapy
          • Others
      • Sweden Model Type Outlook (Revenue in USD Million, 2018 - 2030)
        • Rodent based
          • Rat Models
          • Mice Models
          • Others
        • Non-Rodent based
      • Sweden Indication Outlook (Revenue in USD Million, 2018 - 2030)
        • Autoimmune/inflammation conditions
          • Rheumatoid Arthritis
          • Multiple Sclerosis
          • Osteoarthritis
          • Irritable Bowel Syndrome
          • Others
        • Pain management
          • Chronic pain
          • Acute pain
        • Oncology
          • Blood cancer
          • Solid tumor
            • Syngeneic model
            • Patient derived xenograft
            • Xenograft
          • Others
        • CNS Conditions
          • Epilepsy
          • Parkinson's disease
          • Huntington's disease
          • Stroke
          • Muscular Dystrophy
          • Alzheimer’s Disease
          • Traumatic brain injury
          • Amyotrophic lateral sclerosis (ALS)
          • Spinal Muscular Atrophy
          • Muscle regeneration
          • Other Neurodevelopment Disorders
        • Diabetes
        • Obesity
        • Others
      • Sweden GLP Type Outlook (Revenue in USD Million, 2018 - 2030)
        • GLP Toxicology
        • Non GLP
    • Norway
      • Norway Modality Outlook (Revenue in USD Million, 2018 - 2030)
        • Small Molecules
        • Large Molecules
          • Cell & Gene Therapy
            • CAR T-cell therapies
            • CAR-NK cell therapy
            • TCR-T cell therapy
            • Other
          • RNA Therapy
          • Others
      • Norway Model Type Outlook (Revenue in USD Million, 2018 - 2030)
        • Rodent based
          • Rat Models
          • Mice Models
          • Others
        • Non-Rodent based
      • Norway Indication Outlook (Revenue in USD Million, 2018 - 2030)
        • Autoimmune/inflammation conditions
          • Rheumatoid Arthritis
          • Multiple Sclerosis
          • Osteoarthritis
          • Irritable Bowel Syndrome
          • Others
        • Pain management
          • Chronic pain
          • Acute pain
        • Oncology
          • Blood cancer
          • Solid tumor
            • Syngeneic model
            • Patient derived xenograft
            • Xenograft
          • Others
        • CNS Conditions
          • Epilepsy
          • Parkinson's disease
          • Huntington's disease
          • Stroke
          • Muscular Dystrophy
          • Alzheimer’s Disease
          • Traumatic brain injury
          • Amyotrophic lateral sclerosis (ALS)
          • Spinal Muscular Atrophy
          • Muscle regeneration
          • Other Neurodevelopment Disorders
        • Diabetes
        • Obesity
        • Others
      • Norway GLP Type Outlook (Revenue in USD Million, 2018 - 2030)
        • GLP Toxicology
        • Non GLP
  • Asia Pacific
    • Asia Pacific Modality Outlook (Revenue in USD Million, 2018 - 2030)
      • Small Molecules
      • Large Molecules
        • Cell & Gene Therapy
          • CAR T-cell therapies
          • CAR-NK cell therapy
          • TCR-T cell therapy
          • Other
        • RNA Therapy
        • Others
    • Asia Pacific Model Type Outlook (Revenue in USD Million, 2018 - 2030)
      • Rodent based
        • Rat Models
        • Mice Models
        • Others
      • Non-Rodent based
    • Asia Pacific Indication Outlook (Revenue in USD Million, 2018 - 2030)
      • Autoimmune/inflammation conditions
        • Rheumatoid Arthritis
        • Multiple Sclerosis
        • Osteoarthritis
        • Irritable Bowel Syndrome
        • Others
      • Pain management
        • Chronic pain
        • Acute pain
      • Oncology
        • Blood cancer
        • Solid tumor
          • Syngeneic model
          • Patient derived xenograft
          • Xenograft
        • Others
      • CNS Conditions
        • Epilepsy
        • Parkinson's disease
        • Huntington's disease
        • Stroke
        • Muscular Dystrophy
        • Alzheimer’s Disease
        • Traumatic brain injury
        • Amyotrophic lateral sclerosis (ALS)
        • Spinal Muscular Atrophy
        • Muscle regeneration
        • Other Neurodevelopment Disorders
      • Diabetes
      • Obesity
      • Others
    • Asia Pacific GLP Type Outlook (Revenue in USD Million, 2018 - 2030)
      • GLP Toxicology
      • Non GLP
    • Japan
      • Japan Modality Outlook (Revenue in USD Million, 2018 - 2030)
        • Small Molecules
        • Large Molecules
          • Cell & Gene Therapy
            • CAR T-cell therapies
            • CAR-NK cell therapy
            • TCR-T cell therapy
            • Other
          • RNA Therapy
          • Others
      • Japan Model Type Outlook (Revenue in USD Million, 2018 - 2030)
        • Rodent based
          • Rat Models
          • Mice Models
          • Others
        • Non-Rodent based
      • Japan Indication Outlook (Revenue in USD Million, 2018 - 2030)
        • Autoimmune/inflammation conditions
          • Rheumatoid Arthritis
          • Multiple Sclerosis
          • Osteoarthritis
          • Irritable Bowel Syndrome
          • Others
        • Pain management
          • Chronic pain
          • Acute pain
        • Oncology
          • Blood cancer
          • Solid tumor
            • Syngeneic model
            • Patient derived xenograft
            • Xenograft
          • Others
        • CNS Conditions
          • Epilepsy
          • Parkinson's disease
          • Huntington's disease
          • Stroke
          • Muscular Dystrophy
          • Alzheimer’s Disease
          • Traumatic brain injury
          • Amyotrophic lateral sclerosis (ALS)
          • Spinal Muscular Atrophy
          • Muscle regeneration
          • Other Neurodevelopment Disorders
        • Diabetes
        • Obesity
        • Others
      • Japan GLP Type Outlook (Revenue in USD Million, 2018 - 2030)
        • GLP Toxicology
        • Non GLP
    • China
      • China Modality Outlook (Revenue in USD Million, 2018 - 2030)
        • Small Molecules
        • Large Molecules
          • Cell & Gene Therapy
            • CAR T-cell therapies
            • CAR-NK cell therapy
            • TCR-T cell therapy
            • Other
          • RNA Therapy
          • Others
      • China Model Type Outlook (Revenue in USD Million, 2018 - 2030)
        • Rodent based
          • Rat Models
          • Mice Models
          • Others
        • Non-Rodent based
      • China Indication Outlook (Revenue in USD Million, 2018 - 2030)
        • Autoimmune/inflammation conditions
          • Rheumatoid Arthritis
          • Multiple Sclerosis
          • Osteoarthritis
          • Irritable Bowel Syndrome
          • Others
        • Pain management
          • Chronic pain
          • Acute pain
        • Oncology
          • Blood cancer
          • Solid tumor
            • Syngeneic model
            • Patient derived xenograft
            • Xenograft
          • Others
        • CNS Conditions
          • Epilepsy
          • Parkinson's disease
          • Huntington's disease
          • Stroke
          • Muscular Dystrophy
          • Alzheimer’s Disease
          • Traumatic brain injury
          • Amyotrophic lateral sclerosis (ALS)
          • Spinal Muscular Atrophy
          • Muscle regeneration
          • Other Neurodevelopment Disorders
        • Diabetes
        • Obesity
        • Others
      • China GLP Type Outlook (Revenue in USD Million, 2018 - 2030)
        • GLP Toxicology
        • Non GLP
    • India
      • India Modality Outlook (Revenue in USD Million, 2018 - 2030)
        • Small Molecules
        • Large Molecules
          • Cell & Gene Therapy
            • CAR T-cell therapies
            • CAR-NK cell therapy
            • TCR-T cell therapy
            • Other
          • RNA Therapy
          • Others
      • India Model Type Outlook (Revenue in USD Million, 2018 - 2030)
        • Rodent based
          • Rat Models
          • Mice Models
          • Others
        • Non-Rodent based
      • India Indication Outlook (Revenue in USD Million, 2018 - 2030)
        • Autoimmune/inflammation conditions
          • Rheumatoid Arthritis
          • Multiple Sclerosis
          • Osteoarthritis
          • Irritable Bowel Syndrome
          • Others
        • Pain management
          • Chronic pain
          • Acute pain
        • Oncology
          • Blood cancer
          • Solid tumor
            • Syngeneic model
            • Patient derived xenograft
            • Xenograft
          • Others
        • CNS Conditions
          • Epilepsy
          • Parkinson's disease
          • Huntington's disease
          • Stroke
          • Muscular Dystrophy
          • Alzheimer’s Disease
          • Traumatic brain injury
          • Amyotrophic lateral sclerosis (ALS)
          • Spinal Muscular Atrophy
          • Muscle regeneration
          • Other Neurodevelopment Disorders
        • Diabetes
        • Obesity
        • Others
      • India GLP Type Outlook (Revenue in USD Million, 2018 - 2030)
        • GLP Toxicology
        • Non GLP
    • South Korea
      • South Korea Modality Outlook (Revenue in USD Million, 2018 - 2030)
        • Small Molecules
        • Large Molecules
          • Cell & Gene Therapy
            • CAR T-cell therapies
            • CAR-NK cell therapy
            • TCR-T cell therapy
            • Other
          • RNA Therapy
          • Others
      • South Korea Model Type Outlook (Revenue in USD Million, 2018 - 2030)
        • Rodent based
          • Rat Models
          • Mice Models
          • Others
        • Non-Rodent based
      • South Korea Indication Outlook (Revenue in USD Million, 2018 - 2030)
        • Autoimmune/inflammation conditions
          • Rheumatoid Arthritis
          • Multiple Sclerosis
          • Osteoarthritis
          • Irritable Bowel Syndrome
          • Others
        • Pain management
          • Chronic pain
          • Acute pain
        • Oncology
          • Blood cancer
          • Solid tumor
            • Syngeneic model
            • Patient derived xenograft
            • Xenograft
          • Others
        • CNS Conditions
          • Epilepsy
          • Parkinson's disease
          • Huntington's disease
          • Stroke
          • Muscular Dystrophy
          • Alzheimer’s Disease
          • Traumatic brain injury
          • Amyotrophic lateral sclerosis (ALS)
          • Spinal Muscular Atrophy
          • Muscle regeneration
          • Other Neurodevelopment Disorders
        • Diabetes
        • Obesity
        • Others
      • South Korea GLP Type Outlook (Revenue in USD Million, 2018 - 2030)
        • GLP Toxicology
        • Non GLP
    • Australia
      • Australia Modality Outlook (Revenue in USD Million, 2018 - 2030)
        • Small Molecules
        • Large Molecules
          • Cell & Gene Therapy
            • CAR T-cell therapies
            • CAR-NK cell therapy
            • TCR-T cell therapy
            • Other
          • RNA Therapy
          • Others
      • Australia Model Type Outlook (Revenue in USD Million, 2018 - 2030)
        • Rodent based
          • Rat Models
          • Mice Models
          • Others
        • Non-Rodent based
      • Australia Indication Outlook (Revenue in USD Million, 2018 - 2030)
        • Autoimmune/inflammation conditions
          • Rheumatoid Arthritis
          • Multiple Sclerosis
          • Osteoarthritis
          • Irritable Bowel Syndrome
          • Others
        • Pain management
          • Chronic pain
          • Acute pain
        • Oncology
          • Blood cancer
          • Solid tumor
            • Syngeneic model
            • Patient derived xenograft
            • Xenograft
          • Others
        • CNS Conditions
          • Epilepsy
    • Thailand
      • Thailand Modality Outlook (Revenue in USD Million, 2018 - 2030)
        • Small Molecules
        • Large Molecules
          • Cell & Gene Therapy
            • CAR T-cell therapies
            • CAR-NK cell therapy
            • TCR-T cell therapy
            • Other
          • RNA Therapy
          • Others
      • Thailand Model Type Outlook (Revenue in USD Million, 2018 - 2030)
        • Rodent based
          • Rat Models
          • Mice Models
          • Others
        • Non-Rodent based
      • Thailand Indication Outlook (Revenue in USD Million, 2018 - 2030)
        • Autoimmune/inflammation conditions
          • Rheumatoid Arthritis
          • Multiple Sclerosis
          • Osteoarthritis
          • Irritable Bowel Syndrome
          • Others
        • Pain management
          • Chronic pain
          • Acute pain
        • Oncology
          • Blood cancer
          • Solid tumor
            • Syngeneic model
            • Patient derived xenograft
            • Xenograft
          • Others
        • CNS Conditions
          • Epilepsy
          • Parkinson's disease
          • Huntington's disease
          • Stroke
          • Muscular Dystrophy
          • Alzheimer’s Disease
          • Traumatic brain injury
          • Amyotrophic lateral sclerosis (ALS)
          • Spinal Muscular Atrophy
          • Muscle regeneration
          • Other Neurodevelopment Disorders
        • Diabetes
        • Obesity
        • Others
      • Thailand GLP Type Outlook (Revenue in USD Million, 2018 - 2030)
        • GLP Toxicology
        • Non GLP
  • Latin America
    • Latin America Modality Outlook (Revenue in USD Million, 2018 - 2030)
      • Small Molecules
      • Large Molecules
        • Cell & Gene Therapy
          • CAR T-cell therapies
          • CAR-NK cell therapy
          • TCR-T cell therapy
          • Other
        • RNA Therapy
        • Others
    • Latin America Model Type Outlook (Revenue in USD Million, 2018 - 2030)
      • Rodent based
        • Rat Models
        • Mice Models
        • Others
      • Non-Rodent based
    • Latin America Indication Outlook (Revenue in USD Million, 2018 - 2030)
      • Autoimmune/inflammation conditions
        • Rheumatoid Arthritis
        • Multiple Sclerosis
        • Osteoarthritis
        • Irritable Bowel Syndrome
        • Others
      • Pain management
        • Chronic pain
        • Acute pain
      • Oncology
        • Blood cancer
        • Solid tumor
          • Syngeneic model
          • Patient derived xenograft
          • Xenograft
        • Others
      • CNS Conditions
        • Epilepsy
        • Parkinson's disease
        • Huntington's disease
        • Stroke
        • Muscular Dystrophy
        • Alzheimer’s Disease
        • Traumatic brain injury
        • Amyotrophic lateral sclerosis (ALS)
        • Spinal Muscular Atrophy
        • Muscle regeneration
        • Other Neurodevelopment Disorders
      • Diabetes
      • Obesity
      • Others
    • Latin America GLP Type Outlook (Revenue in USD Million, 2018 - 2030)
      • GLP Toxicology
      • Non GLP
    • Brazil
      • Brazil Modality Outlook (Revenue in USD Million, 2018 - 2030)
        • Small Molecules
        • Large Molecules
          • Cell & Gene Therapy
            • CAR T-cell therapies
            • CAR-NK cell therapy
            • TCR-T cell therapy
            • Other
          • RNA Therapy
          • Others
      • Brazil Model Type Outlook (Revenue in USD Million, 2018 - 2030)
        • Rodent based
          • Rat Models
          • Mice Models
          • Others
        • Non-Rodent based
      • Brazil Indication Outlook (Revenue in USD Million, 2018 - 2030)
        • Autoimmune/inflammation conditions
          • Rheumatoid Arthritis
          • Multiple Sclerosis
          • Osteoarthritis
          • Irritable Bowel Syndrome
          • Others
        • Pain management
          • Chronic pain
          • Acute pain
        • Oncology
          • Blood cancer
          • Solid tumor
            • Syngeneic model
            • Patient derived xenograft
            • Xenograft
          • Others
        • CNS Conditions
          • Epilepsy
          • Parkinson's disease
          • Huntington's disease
          • Stroke
          • Muscular Dystrophy
          • Alzheimer’s Disease
          • Traumatic brain injury
          • Amyotrophic lateral sclerosis (ALS)
          • Spinal Muscular Atrophy
          • Muscle regeneration
          • Other Neurodevelopment Disorders
        • Diabetes
        • Obesity
        • Others
      • Brazil GLP Type Outlook (Revenue in USD Million, 2018 - 2030)
        • GLP Toxicology
        • Non GLP
    • Argentina
      • Argentina Modality Outlook (Revenue in USD Million, 2018 - 2030)
        • Small Molecules
        • Large Molecules
          • Cell & Gene Therapy
            • CAR T-cell therapies
            • CAR-NK cell therapy
            • TCR-T cell therapy
            • Other
          • RNA Therapy
          • Others
      • Argentina Model Type Outlook (Revenue in USD Million, 2018 - 2030)
        • Rodent based
          • Rat Models
          • Mice Models
          • Others
        • Non-Rodent based
      • Argentina Indication Outlook (Revenue in USD Million, 2018 - 2030)
        • Autoimmune/inflammation conditions
          • Rheumatoid Arthritis
          • Multiple Sclerosis
          • Osteoarthritis
          • Irritable Bowel Syndrome
          • Others
        • Pain management
          • Chronic pain
          • Acute pain
        • Oncology
          • Blood cancer
          • Solid tumor
            • Syngeneic model
            • Patient derived xenograft
            • Xenograft
          • Others
        • CNS Conditions
          • Epilepsy
          • Parkinson's disease
          • Huntington's disease
          • Stroke
          • Muscular Dystrophy
          • Alzheimer’s Disease
          • Traumatic brain injury
          • Amyotrophic lateral sclerosis (ALS)
          • Spinal Muscular Atrophy
          • Muscle regeneration
          • Other Neurodevelopment Disorders
        • Diabetes
        • Obesity
        • Others
      • Argentina GLP Type Outlook (Revenue in USD Million, 2018 - 2030)
        • GLP Toxicology
        • Non GLP
  • Middle East & Africa
    • Middle East & Africa Modality Outlook (Revenue in USD Million, 2018 - 2030)
      • Small Molecules
      • Large Molecules
        • Cell & Gene Therapy
          • CAR T-cell therapies
          • CAR-NK cell therapy
          • TCR-T cell therapy
          • Other
        • RNA Therapy
        • Others
    • Middle East & Africa Model Type Outlook (Revenue in USD Million, 2018 - 2030)
      • Rodent based
        • Rat Models
        • Mice Models
        • Others
      • Non-Rodent based
    • Middle East & Africa Indication Outlook (Revenue in USD Million, 2018 - 2030)
      • Autoimmune/inflammation conditions
        • Rheumatoid Arthritis
        • Multiple Sclerosis
        • Osteoarthritis
        • Irritable Bowel Syndrome
        • Others
      • Pain management
        • Chronic pain
        • Acute pain
      • Oncology
        • Blood cancer
        • Solid tumor
          • Syngeneic model
          • Patient derived xenograft
          • Xenograft
        • Others
      • CNS Conditions
        • Epilepsy
        • Parkinson's disease
        • Huntington's disease
        • Stroke
        • Muscular Dystrophy
        • Alzheimer’s Disease
        • Traumatic brain injury
        • Amyotrophic lateral sclerosis (ALS)
        • Spinal Muscular Atrophy
        • Muscle regeneration
        • Other Neurodevelopment Disorders
      • Diabetes
      • Obesity
      • Others
    • Middle East & Africa GLP Type Outlook (Revenue in USD Million, 2018 - 2030)
      • GLP Toxicology
      • Non GLP
    • South Africa
      • South Africa Modality Outlook (Revenue in USD Million, 2018 - 2030)
        • Small Molecules
        • Large Molecules
          • Cell & Gene Therapy
            • CAR T-cell therapies
            • CAR-NK cell therapy
            • TCR-T cell therapy
            • Other
          • RNA Therapy
          • Others
      • South Africa Model Type Outlook (Revenue in USD Million, 2018 - 2030)
        • Rodent based
          • Rat Models
          • Mice Models
          • Others
        • Non-Rodent based
      • South Africa Indication Outlook (Revenue in USD Million, 2018 - 2030)
        • Autoimmune/inflammation conditions
          • Rheumatoid Arthritis
          • Multiple Sclerosis
          • Osteoarthritis
          • Irritable Bowel Syndrome
          • Others
        • Pain management
          • Chronic pain
          • Acute pain
        • Oncology
          • Blood cancer
          • Solid tumor
            • Syngeneic model
            • Patient derived xenograft
            • Xenograft
          • Others
        • CNS Conditions
          • Epilepsy
          • Parkinson's disease
          • Huntington's disease
          • Stroke
          • Muscular Dystrophy
          • Alzheimer’s Disease
          • Traumatic brain injury
          • Amyotrophic lateral sclerosis (ALS)
          • Spinal Muscular Atrophy
          • Muscle regeneration
          • Other Neurodevelopment Disorders
        • Diabetes
        • Obesity
        • Others
      • South Africa GLP Type Outlook (Revenue in USD Million, 2018 - 2030)
        • GLP Toxicology
        • Non GLP
    • Saudi Arabia
      • Saudi Arabia Modality Outlook (Revenue in USD Million, 2018 - 2030)
        • Small Molecules
        • Large Molecules
          • Cell & Gene Therapy
            • CAR T-cell therapies
            • CAR-NK cell therapy
            • TCR-T cell therapy
            • Other
          • RNA Therapy
          • Others
      • Saudi Arabia Model Type Outlook (Revenue in USD Million, 2018 - 2030)
        • Rodent based
          • Rat Models
          • Mice Models
          • Others
        • Non-Rodent based
      • Saudi Arabia Indication Outlook (Revenue in USD Million, 2018 - 2030)
        • Autoimmune/inflammation conditions
          • Rheumatoid Arthritis
          • Multiple Sclerosis
          • Osteoarthritis
          • Irritable Bowel Syndrome
          • Others
        • Pain management
          • Chronic pain
          • Acute pain
        • Oncology
          • Blood cancer
          • Solid tumor
            • Syngeneic model
            • Patient derived xenograft
            • Xenograft
          • Others
        • CNS Conditions
          • Epilepsy
          • Parkinson's disease
          • Huntington's disease
          • Stroke
          • Muscular Dystrophy
          • Alzheimer’s Disease
          • Traumatic brain injury
          • Amyotrophic lateral sclerosis (ALS)
          • Spinal Muscular Atrophy
          • Muscle regeneration
          • Other Neurodevelopment Disorders
        • Diabetes
        • Obesity
        • Others
      • Saudi Arabia GLP Type Outlook (Revenue in USD Million, 2018 - 2030)
        • GLP Toxicology
        • Non GLP
    • UAE
      • UAE Modality Outlook (Revenue in USD Million, 2018 - 2030)
        • Small Molecules
        • Large Molecules
          • Cell & Gene Therapy
            • CAR T-cell therapies
            • CAR-NK cell therapy
            • TCR-T cell therapy
            • Other
          • RNA Therapy
          • Others
      • UAE Model Type Outlook (Revenue in USD Million, 2018 - 2030)
        • Rodent based
          • Rat Models
          • Mice Models
          • Others
        • Non-Rodent based
      • UAE Indication Outlook (Revenue in USD Million, 2018 - 2030)
        • Autoimmune/inflammation conditions
          • Rheumatoid Arthritis
          • Multiple Sclerosis
          • Osteoarthritis
          • Irritable Bowel Syndrome
          • Others
        • Pain management
          • Chronic pain
          • Acute pain
        • Oncology
          • Blood cancer
          • Solid tumor
            • Syngeneic model
            • Patient derived xenograft
            • Xenograft
          • Others
        • CNS Conditions
          • Epilepsy
          • Parkinson's disease
          • Huntington's disease
          • Stroke
          • Muscular Dystrophy
          • Alzheimer’s Disease
          • Traumatic brain injury
          • Amyotrophic lateral sclerosis (ALS)
          • Spinal Muscular Atrophy
          • Muscle regeneration
          • Other Neurodevelopment Disorders
        • Diabetes
        • Obesity
        • Others
      • UAE GLP Type Outlook (Revenue in USD Million, 2018 - 2030)
        • GLP Toxicology
        • Non GLP
    • Kuwait
      • Kuwait Modality Outlook (Revenue in USD Million, 2018 - 2030)
        • Small Molecules
        • Large Molecules
          • Cell & Gene Therapy
            • CAR T-cell therapies
            • CAR-NK cell therapy
            • TCR-T cell therapy
            • Other
          • RNA Therapy
          • Others
      • Kuwait Model Type Outlook (Revenue in USD Million, 2018 - 2030)
        • Rodent based
          • Rat Models
          • Mice Models
          • Others
        • Non-Rodent based
      • Kuwait Indication Outlook (Revenue in USD Million, 2018 - 2030)
        • Autoimmune/inflammation conditions
          • Rheumatoid Arthritis
          • Multiple Sclerosis
          • Osteoarthritis
          • Irritable Bowel Syndrome
          • Others
        • Pain management
          • Chronic pain
          • Acute pain
        • Oncology
          • Blood cancer
          • Solid tumor
            • Syngeneic model
            • Patient derived xenograft
            • Xenograft
          • Others
        • CNS Conditions
          • Epilepsy
          • Parkinson's disease
          • Huntington's disease
          • Stroke
          • Muscular Dystrophy
          • Alzheimer’s Disease
          • Traumatic brain injury
          • Amyotrophic lateral sclerosis (ALS)
          • Spinal Muscular Atrophy
          • Muscle regeneration
          • Other Neurodevelopment Disorders
        • Diabetes
        • Obesity
        • Others
      • Kuwait GLP Type Outlook (Revenue in USD Million, 2018 - 2030)
        • GLP Toxicology
        • Non GLP

Report content

Qualitative Analysis

• Industry overview
• Industry trends
• Market drivers and restraints
• Market size
• Growth prospects
• Porter’s analysis
• PESTEL analysis
• Key market opportunities prioritized
• Competitive landscape
  • Company overview
  • Financial performance
  • Product benchmarking
  • Latest strategic developments

Quantitative Analysis

• Market size, estimates, and forecast from 2018 to 2030
• Market estimates and forecast for product segments up to 2030
• Regional market size and forecast for product segments up to 2030
• Market estimates and forecast for application segments up to 2030
• Regional market size and forecast for application segments up to 2030
• Company financial performance